Covid19
Conditions
Brief summary
Evaluate effect of DAADs on covid-19 disease.
Detailed description
If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19
Interventions
DRUGDAAD Compound
Sofosbuvir , Daclatasvir and ribavirin
Sponsors
Assiut University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
1. HCV patient with or without LC. 2. \>18 years old. 3. Received DAADs at 2019.
Exclusion criteria
1. Combined HCV and HIV infected patients. 2. Combined HCV and HBV infected patients. 3. \< 18 years old. 4. Pregnant or breast-feeding patients. 5. Patients with autoimmune disease. 6. Patients with multiorgan failure, active cancer, renal insufficiency. 7. Patients received immunosuppressive drugs. 8. Immune compromised patients. 9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the effect of DAADs on covid -19 | 12 months (from 1/2/2021 to 1/2/2022) | If chronic HCV patients who received DAADs suspected to be infected by covid-19 by having findings suggest covid 19 infection in MSCT chest or clinically symptoms or confirmed by nasopharyngeal swab . And if infected what about severity , if they need hospital admission or oxygen therapy or mechanical ventilation ,if they still alive or died |
Contacts
Primary ContactEman Adel
Backup ContactNahed Ahmed
Outcome results
None listed